Moberg Pharma’s Nomination Committee appointed

In accordance with the resolution of the Annual General Meeting on May 11, 2015,
the Chairman of the Board has contacted the company’s three largest shareholders
or group of shareholders in terms of votes to form a Nomination Committee. These
shareholders have been invited to appoint one representative each who, together
with the Chairman of the Board, will comprise the Nomination Committee. As not
all of the company’s three largest shareholders or group of shareholders have
wished to appoint such representative, the forth largest shareholder/group of
shareholders have been invited to appoint one representative and so on until the
Nomination Committee now comprises of four members, in accordance with the
resolution of the Annual General Meeting on May 11.
Moberg Pharma’s Nomination Committee ahead of the 2016 Annual General Meeting
comprises:

  · Mats Petterson, Chairman of the Board
  · Per-Olof Edin, appointed by Östersjöstiftelsen
  · Elisabet Jamal Bergström, appointed by Handelsbanken Fonder
  · Anders Rodebjer, appointed by Wolco Invest

Per-Olof Edin has been appointed Chairman of the Nomination Committee. Together,
the Nomination Committee represents 29.1 percent of the shares in Moberg Pharma
as of September 30, 2015.

The Nomination Committee shall submit proposals for resolution by the 2016
Annual General Meeting pertaining to the election of Chairman of the Board, fees
and composition of the Board, auditors’ fees and the election of auditors.

The 2016 Annual General Meeting will be held in Stockholm on May 18.

Shareholders wishing to submit proposals to Moberg Pharma’s Nomination Committee
can do so by e-mail to info@mobergpharma.se by 31 December 2015.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 am (CET) on November 17, 2015.
For additional information, please contact:
Peter Wolpert, CEO, Phone: +46 (0)70 - 735 71 35, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Phone: +46 (0)70 – 766 60 30, Email: anna.ljung@mobergpharma.se
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, Domeboro®, Jointflex®, Vanquish®, and Fergon®. Kerasal
Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment of nail
disorders in the U.S., Canada and several EU markets and is currently being
launched in Southeast Asia. The company is growing organically as well as
through acquisitions. Internal development programs focus on innovative drug
delivery of proven compounds and include two clinical stage assets, MOB-015
(onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has
offices in Stockholm and New Jersey and the company’s shares are listed on the
Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).